Apolipoprotein E genotype in dyslipidemic patients and response of blood lipids and inflammatory markers to alpha-linolenic acid

Angiology

Volumn 56, Issue 1, 2005, Pages 49-60

  Paschos, George K ^a   Yiannakouris, Nikos ^a   Ralliais, Loukianos S ^b   Davies, Ian ^c   Griffin, Bruce A ^c   Panagiotakos, Demosthenes B ^a   Skopouli, Fotini N ^a   Votteas, Vasilios ^d   Zampelas, Antonis ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LINOLEIC ACID; LINSEED OIL; LIPID;

ADULT; AGED; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE MARKER; DYSLIPIDEMIA; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LIPID DIET; MALE;

ADULT; AGED; ALPHA-LINOLENIC ACID; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; DIETARY SUPPLEMENTS; GENOTYPE; GREECE; HOMOZYGOTE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION MEDIATORS; LINSEED OIL; LIPIDS; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; POLYMORPHISM, GENETIC; RISK FACTORS; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 12944266911     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600107     Document Type: Article

References (61)

1. Libby P, Aikawa M, Schonbeck U: Cholesterol and atherosclerosis. Biochim Biophys Acta 1529:299-309, 2000.
2. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126, 1999.
3. Wilson PW, Schaefer EJ, Larson MG, et al: Apolipoprotein E alleles and risk of coronary disease. A metaanalysis. Arterioscler Thromb Vasc Biol 16:1250-1255, 1996.
4. Curtiss LK, Boisvert WA: Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 11:243-251, 2000.
5. Kolovou G, Daskalova D, Mikhailidis DP: Apolipoprotein E polymorphism and Atherosclerosis. Angiology 54:59-71, 2003.
6. Brand K, Mackman N, Curtiss LK: Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest 91:2031-2039, 1993.
7. Kelly ME, Clay MA, Mistry MJ, et al: Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: Production of interleukin 2 with reduced biological activity. Cell Immunol 159:124-139, 1994.
8. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21, 1988.
9. Boerwinkle E, Visvikis S, Welsh D, et al: The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of apolipoprotein E polymorphism in determining levels, variability and covariability of cholesterol, beta-lipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Gene. 27:567-582, 1987.
10. Miettinen TA, Gylling H, Vanhanen H: Serum cholesterol response to dietary cholesterol and apoprotein E phenotype. Lancet 2:1261, 1988.
11. Lopez-Miranda J, Ordovas JM, Mata P, et al: Effect of apolipoprotein E phenotype on diet induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 35:1965-1975, 1994.
12. Ascherio A, Rimm EB, Giovannucci EL, et al: Dietary fat and risk of coronary heart disease in men: Cohort follow-up study in the United States. BMJ 313:84-90, 1996.
13. Hu FB, Stampfer MJ, Manson JE, et al: Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. Am J Clin Nutr 69:890-897, 1999.
14. de Lorgeril M, Renaud S, Mamelle N, et al: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343:1454-1459, 1994.
15. Kromhout D, Keys A, Aravanis C, et al: Food consumption patterns in the 1960s in seven countries. Am J Clin Nutr 49:889-894, 1989.
16. Sandker GW, Kromhout D, Aravanis C, et al: Serum cholesteryl ester fatty acids and their relation with serum lipids in elderly men in Crete and The Netherlands. Eur J Clin Nutr 47:201-208, 1993.
17. Kestin M, Clifton P, Belling GB, et al: n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. Am J Clin Nutr 51:1028-1034, 1990.
18. Wardlaw GM, Snook JT, Lin MC, et al: Serum lipid and apolipoprotein concentrations in healthy men on diets enriched in either canola oil or safflower oil. Am J Clin Nutr 54:104-110, 1991.
19. Pang D, Allman-Farinelli MA, Wong T, et al: Replacement of linoleic acid with alpha-linolenic acid does not alter blood lipids in normolipidaemic men. Br J Nutr 80:163-167, 1998.
20. Bemelmans WJ, Broer J, Feskens EJ, et al: Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: The Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. Am J Clin Nutr 75:221-227, 2002.
21. James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71:343-348, 2000.
22. Rallidis LS, Paschos G, Liakos GK, et al: Dietary α-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 167:237-242, 2003.
23. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 343:1179-1182, 2000.
24. Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242, 1999.
25. Kuller LH, Tracy RP, Shaten J, et al: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144:537-547, 1996.
26. Meek RL, Urieli-Shoval S, Benditt EP: Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function. Proc Natl Acad Sci USA 91:3186-3190, 1994.
27. Clinton SK, Underwood R, Hayes L, et al: Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 140:301-316, 1992.
28. DeGraba TJ: Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology 49:15-19, 1997.
29. Yannakoulia M, Yiannakouris N, Bluher S, et al: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88:1730-1736, 2003.
30. Griffin BA, Caslake MJ, Yip B, et al: Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83:59-67, 1990.
31. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988.
32. Reymer WA, Groenemeyer BE, van de Burg R, et al: Apolipoprotein E genotyping on agarose gels. Clin Chem 41:1046-1047, 1995.
33. Harris WS: n-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 65:1645-1654, 1997.
34. GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 354:447-455, 1999.
35. Harris WS, Park Y, Isley WL: Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidiol 14:9-14, 2003.
36. Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21:495-505, 2002.
37. Nydahl M, Gustafsson IB, Ohrvall M, et al: Similar serum lipoprotein cholesterol concentrations in healthy subjects on diets enriched with rapeseed and with sunflower oil. Eur J Clin Nutr 48:128-137, 1994.
38. Singer P, Wirth M, Berger I: A possible contribution of decrease in free fatty acids to low serum triglyceride levels after diets supplemented with n-6 and n-3 polyunsaturated fatty acids. Atherosclerosis 83:167-175, 1990.
39. Singh RB, Niaz MA, Sharma JP, et al: Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 11:485-491, 1997.
40. Caughey GE, Mantzioris E, Gibson RA, et al: The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 63:116-122, 1996.
41. Thies F, Miles EA, Nebe-von-Caron G, et al: Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids 36:1183-1193, 2001.
42. Kew S, Banerjee T, Minihane AM, et al: Lack of effect of foods enriched with plant- or marine-derived n-3 fatty acids on human immune function. Am J Clin Nutr 77:1287-1295, 2003.
43. Ordovas JM: The genetics of serum lipid responsiveness to dietary interventions. Proc Nutr Soc 58:171-187, 1999.
44. Minihane AM, Khan S, Leigh-Firbank EC, et al: ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20:1990-1997, 2000.
45. Nestel PJ, Pomeroy SE, Sasahara T, et al: Arterial compliance in obese subjects is improved with dietary plant n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Thromb Vasc Biol 17:1163-1170, 1997.
46. Deiana L, Res GM, Carru C, et al: Lack of influence of apolipoprotein E4 on lipoprotein levels in the island population of Sardinia. Eur J Clin Invest 28:290-294, 1998.
47. Aguilar CA, Talavera G, Ordovas JM, et al: The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a native American population following its traditional lifestyle. Atherosclerosis 142:409-414, 1999.
48. Kolovou G, Yiannakouris N, Hatzivassiliou M, et al: Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients with coronary artery disease. Curr Med Res Opin 18:118-124, 2002.
49. Becker S, Warren MK, Haskill S: Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum free cultures. J Immunol 139:3703-3709, 1987.
50. 2 in non-adherent human monocytes. J Immunol 158:351-358, 1997.
51. McCarty MF: Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 52:465-477, 1999.
52. Herity NA: Interleukin 6: A message from the heart. Heart 84:9-10, 2000.
53. Manttari M, Manninen V, Palosuo T, et al: Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men. Atherosclerosis 156:237-238, 2001.
54. Bach-Ngohou K, Nazih H, Nazih-Sanderson F, et al: Negative and independent influence of apolipoprotein E on C-reactive protein (CRP) concentration in obese adults. Potential anti-inflammatory role of apoE in vivo. Int J Obes Relat Metab Disord 25:1752-1758, 2001.
55. James RW, Boemi MG, Giansanti R, et al: Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Tromb 13:1456-1459, 1993.
56. Bailleul S, Couders R, Landais V, et al: Direct phenotyping of human apolipoprotein E in plasma: Application to population frequency distribution in Paris (France). Hum Hered 43:159-165, 1993.
57. Kolovou GD, Daskalova DC, Hatzivassiliou M, et al: The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population-implications for the interpretation of similar studies. Angiology 54:51-58, 2003.
58. Schiele F, De Bacquer D, Vincent-Viry M, et al: Apolipoprotein E serum concentration and polymorphism in six European countries: The ApoEurope Project. Atherosclerosis 152:475-488, 2000.
59. Trichopoulou A, Costacou T, Bamia C, et al: Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 348:2599-2608, 2003.
60. Masson LF, McNeill G, Avenell A: Genetic variation and the lipid response to dietary intervention: A systematic review. Am J Clin Nutr 77:1098-1111, 2003.
61. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 136:3716-3723, 1986.